To date, there are several biomarkers being studied that may help to predict the benefit of CTLA-4 and PD-1/PD-L1 inhibition, including PD-L1 expression in tumor and immune cells and high TMB in patients with dMMR, MSI-H or HR deficiency. Here, CTLA4 is linked to neoplasm.